Cipla Share Price

₹ 1,403.80

-₹2.00 (-0.14%)
1D
Last updated 09 Nov, 2026, 15:51 IST
NSE: CIPLA
|
Pharmaceuticals

Cipla Share Price Today

As of 10 Nov 2026, Cipla share price is ₹1,403.80. The stock opened at ₹1,408.00, compared to its previous close of ₹1,405.80. During today's trading session, Cipla share price moved in the range of ₹1,397.50 to ₹1,421.40, with an average price of ₹1,409.45 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,165.70 and a high of ₹1,539.70. On the performance front, Cipla share price has increased by 4.22% over the last six months and is down 6.77% on a year-on-year basis.

Share price over the last 1 day fell from 1408.20 to 1403.80, ranging between 1397.70 and 1419.90.
₹1,397.50
0.14% down today
₹1,421.40
1D LOW
1D HIGH

Cipla Stock Insights

Latest Earning
Op Profit TrendUp by 8.82% QoQ
Latest Earning
Net Profit TrendUp by 8.82% QoQ
Latest Earning
Revenue TrendUp by 3.07% QoQ
Stock Performance
OutperformingBeat Nifty by 3.03 % in last 6 month
Shareholding Pattern
PromoterPromoter decreased stake by 0.03%
Shareholding Pattern
DIIDII increased stake by 0.59%
Shareholding Pattern
FIIFII increased stake by 0.19%
Technical Indicators
Price breakoutPrice has broken above resistance on 1 Day interval.
Cipla stock performance
Open₹1,408.00
High₹1,421.40
Low₹1,397.50
Prev. close₹1,405.80
Cipla trading activity
Volume17,06,347
Average traded price₹1,405.85
Last traded time03:51:36 09 Nov
Last traded quantity19
Circuit
L
H
₹1,362.40
₹1,446.60
52-week
L
H
₹1,165.70
₹1,539.70
Mkt Cap Cr
1,13,988.97
P/E
39.95
P/B
3.22
ROA
6.6%
ROE
8.18%
ROCE
10.8%
Quick Ratio
2.5
EV/EBITDA
21.52

Based on fundamentals, this stock's

Performance: 4 out of 5, Good
Performance
Good
Cipla outperforming most market indices
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Cipla appears overvalued compared to its peers
Earnings: 4 out of 5, Good
Earnings
Good
Cipla revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,59,496.6441.825.159.61%13.79%18.65%2.3123.35
Divis Laboratories2,94,145.8287.4716.3413.32%15.32%19.56%3.562.27
Torrent Pharmaceuticals1,81,473.5086.469.884.7%11.42%11.37%0.7534.53
Laurus Labs1,28,054.0096.1121.1311.58%22.11%20.91%0.6853.3
Zydus Lifesciences1,19,700.4627.824.37.63%15.1%14.86%0.9116.0
Dr. Reddy's Laboratories1,14,532.4441.432.954.79%7.21%8.58%1.3519.35
Mankind Pharma1,04,913.4547.036.057.82%12.76%14.68%0.7425.47
Aurobindo Pharma1,03,395.4126.062.646.46%10.13%12.76%1.1512.49
Lupin91,229.9517.473.7913.08%21.65%24.54%1.4210.19
Glenmark Pharma73,237.3050.476.536.78%18.07%19.86%1.2326.52

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Cipla Company Background

ISIN
INE059A01026
Sector Market Cap
₹ 113,988.97 Cr

Established in: 1935

Managing Director: Achin Gupta

Cipla Limited is an Indian multinational pharmaceutical company established in 1935 and headquartered in Mumbai, Maharashtra. The company focuses on developing medicines to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical illnesses.

Cipla has around 47 manufacturing facilities across the world, sells its products in over 86 countries, and is the third largest drug producer in India. The company also sells active pharmaceutical ingredients to other manufacturers, along with personal care products, including anti-depressant escitalopram oxalate, lamivudine, and fluticasone propionate. Cipla is the largest manufacturer of antiretroviral drugs in the world.

The company launched their IPO and went public in 1979, and is now listed on both Indian stock exchanges, BSE and NSE. Cipla Limited is a constituent of the BSE Sensex and the NSE CNX Nifty. The company’s Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.

History of Cipla Limited

Khawaj Abdul Hamied, the founder of Cipla, met with Mahatma Gandhi in the early 1920s and decided to contribute to the Swadeshi movement by pursuing a Doctorate in chemistry. In 1935, Khawaj Abudl Hamied founded Cipla as the Chemical, Industrial and Pharmaceutical Laboratories in Mumbai, Maharashtra.

Business Segments of Cipla Limited

Cipla Limited has two primary business segments: Pharmaceutical and New Ventures.

  • Pharmaceutical Segment This segment is the core revenue driver for Cipla and oversees its generic and active pharmaceutical ingredients operations. It manufactures prescription drugs, generic medications and active pharmaceutical ingredients for its own use and for other manufacturers as well.

  • New Ventures Segment This division focuses on the long-term sustainability of the company by entering into new and specialised medical sectors. The subsidiary company, Cipla Health, is producing fast-moving consumer health and wellness products. The company is now focusing on developing recombinant proteins and advanced biologics to target chronic and severe diseases.

Cipla Limited is pioneering drug-device combinations, proprietary formulations and targeted regenerative therapies for critical care and respiratory delivery systems.

Subsidiaries of Cipla Limited

Cipla Limited has a network of Indian and international subsidiaries. The following are the subsidiaries of Cipla Limited.

  • Cipla Health Limited
  • Cipla Pharmaceuticals Limited
  • Cipla Digital Health Limited
  • Goldencross Pharma Limited
  • Jay Precision Pharmaceuticals Private Limited
  • Medispray Laboratories Private Limited
  • Meditab Specialities Limited
  • Sitec Labs Limited
  • Cipla BioTec Limited
  • Cipla USA Incorporation
  • Cipla Medpro South Africa (Pty) Limited
  • Cipla Quality Chemical Industries Limited (Uganda)
  • Cipla Europe NV
  • Cipla Gulf FZ-LLC / Cipla Middle East Pharmaceuticals FZ-LLC (UAE)

Awards and Recognition Received by Cipla Limited

The following are the awards and recognitions received by Cipla Limited over the years.

  • 1980: Cipla was awarded the Chemexcil Award for Excellence in exports.
  • 2006: Cipla was awarded the Dun & Bradstreet American Express Corporate Awards.
  • 2007: Cipla was included in the Forbes 200 'Best under a billion' list of best small Asian companies.
  • 2012: Cipla received the Thomson Reuters India Innovation Award.
  • 2015: Cipla stood third in India's Most Reputed Brands in the Pharmaceutical sector list in a study conducted by BlueBytes.
  • 2025: Cipla received the Economic Times Healthcare Award for Excellence in Health and Wellness (Product & Technology).
  • 2026: Cipla was honoured with the Outstanding Pharma Project Culture (Organisation) award.

Cipla Financial Highlights

  • Revenue: Cipla reported revenue of ₹29,044.60 crore in FY26 vs ₹28,409.49 crore in FY25. It showed an increase of 2.24% on a yearly basis.
  • Operating Profit: Cipla reported an operating profit of ₹5,223.63 crore in FY26 vs ₹6,820.81 crore in FY25. It showed a decrease of 23.42% on a year-on-year basis.
  • Net Profit: Cipla reported a net profit of ₹3,869.79 crore in FY26 vs ₹5,291.05 crore in FY25. It showed a decrease of 26.86% on a yearly basis.

Cipla Quarterly Result Highlights

  • Cipla reported revenue of ₹7,555.09 crore in Sep 2026, compared with ₹7,330.18 crore in Jun 2026, representing an increase of 3.07% on a quarter-on-quarter (QoQ) basis.
  • Cipla reported an operating profit of ₹1,177.34 crore in Sep 2026, compared with ₹1,081.93 crore in Jun 2026, representing an increase of 8.82% on a quarter-on-quarter (QoQ) basis.
  • Cipla reported a profit of ₹856.52 crore in Sep 2026, compared with ₹787.10 crore in Jun 2026, reflecting an increase of 8.82% on a QoQ basis.
  • The earnings per share (EPS) of Cipla stood at ₹48.03 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
29.21%
FII
20.25%
Other DII
14.16%
Retail and other
15.61%
Mutual funds
20.78%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202523.93%
Mar 202622.56%
Jun 202620.21%
Sep 202620.25%

Cipla Investment Returns

1 day
-0.14%
1 week
+0.49%
1 month
+7.90%
1 year
-6.77%
3 years
+13.38%
5 years
+53.56%

Cipla Share Price History

Cipla share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
09 Nov 26
₹1,408.00 / ₹1,403.80
-0.14%
08 Nov 26
₹1,414.50 / ₹1,405.80
-0.37%
06 Nov 26
₹1,387.00 / ₹1,411.00
+0.49%
05 Nov 26
₹1,405.00 / ₹1,404.10
+0.15%
Show more

Cipla Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹28,162.59₹27,547.62₹25,774.09₹22,753.12
Other Income₹882.01₹861.87₹746.57₹475.45
Total Revenue₹29,044.60₹28,409.49₹26,520.66₹23,228.57
Total Expenses₹23,545.06₹21,588.68₹20,623.94₹19,007.80
Profit Before Tax₹5,223.63₹6,820.81₹5,701.90₹4,038.35
Tax₹1,353.84₹1,529.76₹1,546.59₹1,202.86
Profit After Tax₹3,869.79₹5,291.05₹4,155.31₹2,835.49
EPS - Basic₹48.03₹65.29₹51.05₹34.72
EPS - Diluted₹48.00₹65.24₹51.01₹34.69

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹5,223.63₹6,820.81₹5,896.72₹4,220.77
Income before WC changes₹5,751.44₹7,338.55₹6,537.49₹5,098.96
Change in Assets-₹878.28-₹1,065.48-₹968.81-₹541.21
Change in Liabilities₹653.06₹400.01₹162.71-₹18.21
Change in WC-₹225.22-₹665.47-₹806.10-₹559.42
Cash flow from Operations₹3,940.02₹5,004.98₹4,133.91₹3,237.65
Cash flow from Investing-₹2,326.13-₹3,691.14-₹2,988.03-₹2,388.51
Cash flow from Financing-₹1,233.65-₹1,292.79-₹1,200.43-₹958.29
Total Cash Flow₹380.24₹21.05-₹54.55-₹109.15
Cash (Start of the year)₹542.65₹512.34₹561.33₹658.11
Cash (End of the year)₹1,015.39₹542.65₹512.34₹561.33

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹18,350.12₹14,138.07₹13,325.37₹12,658.22
Current Assets₹24,145.86₹23,248.97₹19,392.45₹16,805.06
Total Assets₹42,495.98₹37,387.04₹32,717.82₹29,463.28
Current Liabilities₹7,013.59₹5,483.96₹5,245.77₹5,109.67
Net Current Asset₹17,132.27₹17,765.01₹14,146.68₹11,695.39
Non-Current Liabilities₹962.15₹613.83₹669.72₹640.07
Equity Capital₹34,520.24₹31,289.25₹26,802.33₹23,713.54
Total Equity & Liabilities₹42,495.98₹37,387.04₹32,717.82₹29,463.28

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹18,979.95₹19,044.85₹16,574.34₹14,345.34
Other Income₹1,122.65₹984.72₹1,070.66₹456.79
Total Revenue₹20,102.60₹20,029.57₹17,645.00₹14,802.13
Total Expenses₹15,222.29₹13,855.41₹12,698.03₹11,610.63
Profit Before Tax₹4,635.94₹6,468.82₹4,946.97₹3,005.60
Tax₹1,120.76₹1,311.17₹1,232.78₹861.54
Profit After Tax₹3,515.18₹5,157.65₹3,714.19₹2,144.06
EPS - Basic₹43.52₹63.87₹50.51₹31.15
EPS - Diluted₹43.49₹63.82₹50.46₹31.12

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹4,635.94₹6,468.82₹5,432.14₹3,685.17
Income before WC changes₹4,390.60₹5,888.51₹5,089.23₹3,954.74
Change in Assets-₹561.42-₹1,477.24-₹349.74₹133.62
Change in Liabilities₹224.92₹248.08₹211.44₹30.95
Change in WC-₹336.50-₹1,229.16-₹138.30₹164.57
Cash flow from Operations₹2,831.69₹3,300.99₹3,726.77₹3,035.05
Cash flow from Investing-₹1,344.09-₹2,308.53-₹2,882.82-₹2,757.95
Cash flow from Financing-₹1,321.90-₹1,073.93-₹708.83-₹424.77
Total Cash Flow₹165.70-₹81.47₹135.12-₹147.67
Cash (Start of the year)₹82.74₹164.52₹29.48₹177.29
Cash (End of the year)₹248.80₹82.74₹164.52₹29.48

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹20,581.07₹17,196.50₹16,195.39₹14,225.34
Current Assets₹17,912.02₹18,369.22₹14,857.84₹13,371.13
Total Assets₹38,493.09₹35,565.72₹31,053.23₹27,596.47
Current Liabilities₹3,871.78₹3,183.42₹2,862.25₹2,699.74
Net Current Asset₹14,040.24₹15,185.80₹11,995.59₹10,671.39
Non-Current Liabilities₹420.20₹283.06₹217.06₹258.64
Equity Capital₹34,201.11₹32,099.24₹27,973.92₹24,638.09
Total Equity & Liabilities₹38,493.09₹35,565.72₹31,053.23₹27,596.47
* All values are in INR Crore
Cipla market depth
Bid quantityBid priceAsk priceAsk quantity
001403.8875
0000
0000
0000
0000
Total bid quantity0
Total ask quantity875
Cipla technical summary
Bearish indicators5
Neutral indicators2
Bullish indicators1
OverallStrong Bearish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
64.59
Neutral
ATR (14)
27.8
Neutral
STOCH(9,6)
88.53
Bearish
STOCH RSI (14)
91.25
Bearish
ADX(9)
34.15
Bearish
UO(9)
79.77
Bearish
ROC(12)
5.63
Bullish
WillR(14)
-8.53
Bearish
Period
Simple value
Exponential vaue
5D
1403.96
1401
10D
1385.93
1387.51
20D
1356.49
1372.46
50D
1367.5
1373.47
100D
1402.52
1378.99
Volume trend — traded volume by day
9 Nov17L
8 Nov0L
6 Nov15L
5 Nov12L
4 Nov13L
3 Nov17L
Average12L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Cipla
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Cipla

Fund name
AUM
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
9.40%
ICICI Prudential Nifty Pharma Index Fund
8.99%
DSP Healthcare Fund
8.06%

Cipla Returns Calculator

Ex-date: 05 Jun 2026

Cipla Latest News

1 week ago
Cipla Q2 FY27 results: Net profit declines 35% YoY; firm invests ₹423 crore in R&D
2 weeks ago
Top gainers and losers, October 22: Nestle, Eternal tumble 3%; Bajaj Finance shares jump 3%
3 weeks ago
Dr Reddy’s, Torrent Pharma, Zydus Life: Pharma stocks to post resilient growth in Q2 earnings despite pricing headwinds
1 month ago
Top gainers and losers, September 24: HDFC LIC, Bajaj Finance tumble 6%, Cipla rises over 1%; check list
1 month ago
Cipla, Vardhaman Textiles and Siemens Energy India shares cross 200 EMA despite weak market sentiment
1 month ago
NIFTY Midcap 100 and NIFTY Smallcap 100 outshine NIFTY50 so far in 2026; here's why
2 months ago
Top gainers and losers, Sept 3: TechM, Cipla drop 2%; Adani Ports, Axis Bank, HDFC Bank gain over 1%
2 months ago
SENSEX, NIFTY50 end lower for fourth straight session as IT, FMCG stocks extend losses
2 months ago
Stocks to watch, August 26: Varun Beverages, Groww, Welspun Corp, Hindustan Copper, Emami, Cyient
2 months ago
NIFTY Pharma surges over 3% on India-US trade deal boost; Cipla, Sun Pharma, Dr Reddy's, others gain
Showing news item 1 of 10

Top Gainers

CHEMPLASTS Share Price
₹237.83
+24.42 (+11.44%)
DATAPATTNS Share Price
₹4025.00
+321 (+8.67%)
QUESS Share Price
₹345.70
+27.15 (+8.52%)
SPARC Share Price
₹210.80
+13.77 (+6.99%)
GLAXO Share Price
₹2710.00
+170.4 (+6.71%)
See more

Top Losers

RRKABEL Share Price
₹1969.40
-146 (-6.9%)
FINCABLES Share Price
₹1232.40
-76.6 (-5.85%)
ALIVUS Share Price
₹1474.40
-84.3 (-5.41%)
TTML Share Price
₹39.33
-2.18 (-5.25%)
STLTECH Share Price
₹670.95
-35.3 (-5%)
See more

Cipla Share Price FAQs

Please be aware that Cipla stock prices are subject to continuous fluctuations due to various factors.